FeesSafety
Pluang+

Solana validators with 62.6% stake connect to DoubleZero network with 10+ Tbps fiber capacity

Protocol Fundamentals
23 Oct 2026
Tokenpost
View Source
Neutral
Solana validators with 62.6% stake connect to DoubleZero network with 10+ Tbps fiber capacity

On August 22, validators representing 62.6% of Solana's stake weight connected to DoubleZero, a private transport network for blockchains. The network also boasts over 10 terabits per second of aggregate fiber capacity, enhancing blockchain data transmission. DoubleZero's mainnet beta launched in October 2025, aiming to improve performance and routing for distributed systems. This connection highlights growing infrastructure support for Solana's blockchain operations.

The story on DoubleZero Connected Validators and Solana stake provides context for cryptocurrency market activity. For readers following major cryptocurrencies on Pluang, as of Oct 23, 2026 19:01 WIB, 26 out of 50 major cryptocurrencies rose while 23 fell. Bitcoin Cash (BCH) rose 2.72% to Rp5.132.608 with a typical hold time of 69 days, and Pluang order activity showed 73% buy orders.

More News

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...

Company Fundamentals
Bullish
58 minutes ago
Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...

Company Fundamentals
Bullish
58 minutes ago
Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...

Market News
Bullish
58 minutes ago
eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...

Others
Neutral
1 hour ago
Balchem posts Q3 2026 sales of $290.7M, net earnings up 16%, driven by growth in all segments.

Balchem posts Q3 2026 sales of $290.7M, net earnings up 16%, driven by growth in all segments.

Balchem Corporation reported strong Q3 2026 results with net sales of $290.7 million, up 8.6% year-over-year, and net earnings of $46.7 million, a 16% increase. Growth was driven by all three segments: Human Nutrition and Health, Animal Nutrition and...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App